An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

313

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloproliferative Disorders
Myelofibrosis
Primary Myelofibrosis
Post-Polycythemia Vera Myelofibrosis
Anemia

Interventions

DRUG: ACE-536
OTHER: Placebo

Sponsor

Celgene